Key Takeaways
- Strong quarter, guidance raised: India business grew 12.4% YoY and the U.S. business grew 28% YoY, prompting management to raise full-year U.S. growth guidance from mid-single-digit to low double-digit.
- Margins expanded despite investment cycle: EBITDA margin reached 23%, up 22.3% YoY, even as the company began absorbing costs from new ventures in U.S. CDMO and Medtech.
- The U.S. story is shifting from base to launches: The base business is flattish, with volume growth offset by price erosion, so growth now depends entirely on new launches like sacubitril/valsartan.
- H2 will carry new cost burdens: At least ₹100 crores in U.S. CDMO opex and ₹50-60 crores in lost Sikkim GST benefits will hit the P&L in the second half, partially offsetting the strong H1 margin performance.
- What to watch next quarter: The pace of price erosion on sacubitril/valsartan as competitors enter, the revenue ramp at the newly operational U.S. CDMO plant, and whether the anti-infective season strength carries into Q3.
India Business: Market Leadership and Outperformance
- Volume and brand-driven growth: India sales grew 12.4% YoY, backed by strong launches and fast-growing key brands, with Alkem becoming the number one company in the Acute segment per IQVIA SSA data for Q2 FY26.
- Broad therapy leadership: The company outperformed the IPM in 6 out of 11 therapies, and ranks number two in IPM for new product launches over the last 12 months.
- GST transition absorbed: The government's GST revision was a welcome move that makes medicines more affordable, though it caused a transient supply chain disruption and a one-time impact of ₹10-12 crores from trade arrangements.
- Sikkim benefit loss is structural: The ongoing loss of the Sikkim facility's tax benefit will be substantial, at roughly ₹50-60 crores in H2, or ₹25-30 crores per quarter going forward.
- GLP-1 opportunity is imminent: Clinical trials for the diabetes indication are completed and subject expert committee approval has been received; management is waiting for formal marketing authorization and is very hopeful for approval very shortly.
Vikas Gupta: "I have always maintained that we will continue to outperform the market at least by 100 to 150 basis points."
U.S. Business: Launch-Dependent Growth with Price Erosion Risk
- Growth revised sharply upward: U.S. sales grew 28% YoY to ₹764.9 crores, and full-year growth guidance was raised to low double-digit, around 10% to 11%, from an earlier mid-single-digit expectation.
- Base business is flattish: Excluding new launches, the base portfolio has been very flattish, with volume growth offset by price erosion, making new launches the sole growth driver.
- Sacubitril/valsartan is the quarter's anchor launch: The most meaningful U.S. launch was done in Q2 and has contributed to growth this year, with at least 3 or 4 more launches planned for H2.
- Price erosion is a when, not if: Management acknowledged that price erosion on sacubitril/valsartan will happen as more players enter, though the timing is uncertain, and the company expects to be fairly competitive.
- Pipeline gated by litigation: Tolvaptan (Jynarque) has tentative approval but launch is slated for FY27-28 due to ongoing litigation with the innovator; Mirabegron will launch only after patent expiry under a settlement agreement.
Vikas Gupta: "price erosion in a new launch in U.S. is a market phenomenon, right? This is only first quarter of players entering. So the question is whether price erosion will happen, price erosion will happen. But when it starts tracking, whether it is 3 months from now, 6 months from now, we'll wait and see."
CDMO: Early Days with a Defined Ramp Path
- U.S. plant now operational: The Enzene U.S. CDMO plant started operations in September, with pre-work revenue realized while opex was mostly capitalized; from Q3 onwards, opex of roughly ₹50 crores per quarter will hit the P&L.
- Revenue target set: The company expects to close between ₹70 crores to ₹80 crores of revenue from the Enzene CDMO U.S. business for the full year, with a target annual run rate of ₹300 crores over the next 12 to 18 months from current production capacity.
- Breakeven timeline: The plant is expected to reach breakeven in 12 to 18 months.
- Work is development, not commercial: The U.S. CDMO work is product development, not commercial-scale manufacturing, and the ₹300 crores target is from development work, which carries high gross margins with low material cost and favorable EBITDA margins.
- Scale-up optionality is real: Management stated that 3 to 6 months down the line, if the opportunity warrants scaling up and further investment, they will not shy away from taking that call.
- Domestic Enzene is already contributing: The Enzene Pune plant's domestic operations are already at breakeven and EBITDA positive.
Vikas Gupta: "we see a good opportunity in that business. And at this stage, because we've just made the plant operational, first, we would like to maximize the output of this plant. But say, 3 to 6 months down the line, if we see an opportunity and if that warrants us to make and scale up that business and make further investments, we won't shy away."
Margins: H1 Strength, H2 Absorption
- EBITDA margin expanded to 23%: EBITDA grew 22.3% YoY, with improved gross margins and operating leverage contributing to a stronger EBITDA profile, while new investments in the U.S. CDMO plant were not fully operationalized in H1 and therefore carried minimal expense.
- Gross margin held at 65% despite mix shift: Gross margin remained at roughly 65% even as international business grew at a higher rate than domestic, because API prices declined in Q2 versus both Q1 and the prior year, offsetting the mix headwind from domestic business carrying better gross margins than international.
- Other expenses jumped sequentially: Other expenses rose sharply by roughly ₹200 crores sequentially, mainly due to marketing expenses peaking in Q2 and the inclusion of two new subsidiaries, Bombay Ortho and Adroit, in consolidated results.
- H2 will absorb new cost layers: Management expects at least ₹100 crores of operational expenditure from the U.S. CDMO plant in H2, plus ₹50-60 crores in GST impact from the Sikkim facility, with Q3 and Q4 other expenses guided to around ₹900-905 crores including Enzene and Medtech.
- R&D spend is back-end loaded: R&D was at 3.3% in Q2, but most filings occur in Q4, so R&D expense will catch up in H2 and is expected to land within the 4% to 5% range for the full year.
- Medium-term margin ambition intact: Management reiterated a year-on-year margin improvement of at least 1%, with roughly 50 bps expansion expected this year despite investments, and a full 1 percentage point expansion from FY27 onwards, inclusive of planned investments in Medtech and CDMO.
Vikas Gupta: "I've always maintained that year-on-year, we should look at least a 1% improvement in our overall margins. And I think we are pretty much on track for that."
International and New Ventures: Diversification in Motion
- Non-U.S. markets delivered 32.4% YoY growth: Growth was driven by opportunities in markets like Germany and Australia, with the first half described as very good and full-year growth expected in the high teens, easily upwards of close to 20%.
- Medtech is a small drag today: The Medtech business has just started and posted an EBITDA loss of roughly ₹5.5 crores in the quarter, with breakeven expected only by FY28 and opex losses described as not very significant.
- Adroit integration underway: The branded business is already operating at breakeven and will be merged with the domestic business.
- M&A appetite is India-focused: Management stated that India is the core market and the company is continuously on the lookout for the right opportunities at the right value where more value can be created, supported by good cash on the balance sheet.
- GLP-1 beyond India is years away: Launch in other markets is expected only a couple of years from now, with U.S. filing likely taking roughly 2 years to secure approval.
Vikas Gupta: "We will be a meaningful player over there... I'm sure everybody would be inking it's a pretty large opportunity, and I'm sure there is room for meaningful presence for more than one player in that market."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India growth outperformance | Outperform IPM by at least 100 to 150 bps; double-digit growth assuming market grows at 8% to 8.5% | FY26 and FY27 |
| Full-year EBITDA margin | 19.5% to 20% | FY26 |
| U.S. revenue growth | Low double-digit, around 10% to 11% | FY26 |
| Non-U.S. revenue growth | High teens, upwards of close to 20% | FY26 |
| U.S. CDMO revenue | Close between ₹70 to 80 crores | FY26 |
| U.S. CDMO annual run rate | ₹300 crores from current production capacity | Next 12 to 18 months |
| U.S. CDMO breakeven | Plant reaches breakeven | 12 to 18 months |
| R&D spend | Within 4% to 5% of revenue | FY26 |
| H2 other expenses (quarterly) | Around ₹900 to 905 crores including Enzene and Medtech | Q3 and Q4 FY26 |
| Sikkim GST impact run-rate | ₹25 to 30 crores per quarter | Ongoing from H2 FY26 |
| Effective tax rate | 35% to 38% as company exits MAT after March 2026 | FY27 |
| Medium-term margin expansion | At least 1 percentage point year-on-year improvement | FY27 onwards |
| Medtech breakeven | Business reaches breakeven | FY28 |
| Tolvaptan (Jynarque) launch | Launch after litigation resolution | FY27-28 |
| U.S. H2 launches | At least 3 or 4 more launches | H2 FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹4,001 cr, all-time high, +17.2% YoY |
| India sales | ₹2,766 cr, +12.4% YoY |
| U.S. sales | ₹764.9 cr, +28% YoY |
| Non-U.S. sales | ₹424.1 cr, +32.4% YoY |
| EBITDA | ₹920.8 cr, +22.3% YoY; margin 23% |
| Net profit after minority interest | ₹765.1 cr, +11.1% YoY |
| R&D expenses | ₹130.2 cr, 3.3% of total revenue |
| Gross margin | 65% in Q2; 64% to 65% expected for H2 and full year |
| Full-year EBITDA margin guidance | 19.5% to 20% |
| India business growth outlook | 100 to 150 bps above IPM growth, sustained outperformance expected |
| U.S. business full-year growth expectation | 10% to 11%, low double-digit, up from earlier mid-single-digit expectation |
| Non-U.S. constant currency growth | ~28% (per an analyst's math), with currency gain of 4% to 4.5% |
| Enzene U.S. CDMO revenue booked so far | ₹40 cr to ₹45 cr; ~₹20 cr per quarter expected for next 2 quarters |
| Enzene U.S. CDMO annual run rate target | ₹300 cr, expected in next 12 to 18 months |
| Enzene U.S. CDMO opex per quarter | ~₹50 cr, starting Q3 FY26 |
| GST impact from loss of Sikkim benefit | ₹50 cr to ₹60 cr in H2 FY26; ~₹25 cr to ₹30 cr per quarter |
| GST one-time trade arrangement impact | ₹10 cr to ₹12 cr |
| Medtech revenue | ~₹2.5 cr (900 knee replacements) |
| Medtech opex and EBITDA loss | Opex ₹8 cr to ₹9 cr; EBITDA loss ~₹5.5 cr |
| Adroit revenue run rate | ~₹15 cr for the quarter, at breakeven |
| U.S. launches in H1 FY26 | 4 launches; sacubitril/valsartan most meaningful |
| U.S. launches planned for H2 FY26 | At least 3 to 4 more |
| Effective tax rate expectation for FY27 | 35% to 38% |
| MAT credit on balance sheet | More than ₹1,500 cr; no significant cash outflow for next 1 to 2 years |
| Other expenses expected for Q3 and Q4 FY26 | ~₹900 cr to ₹905 cr per quarter, including Enzene and Medtech |